[A clinical trial of bromazepam (author's transl)].
Bromazepam was studied in 32 patients with neurotic anxiety. Daily doses varied between 6 and 12 mg on average. Bromazepam was associated with neuroleptic drugs in 2 cases and with tricyclic antidepressants in 12 cases. Satisfactory results were obtained in 72% of the patients, particularly those with anxiety neurosis and reactional anxiety. The drug was tolerated; transient drowsiness was well noted in 3 cases and some degree of euphoria in 2 cases. Bromazepam appears to be a quick-acting, purely anxiolytic drug, with effects perceptible after 2 or 3 days of the treatment. Its lack of sedative action makes it particularly useful in ambulatory patients.
D000293:Adolescent; D000328:Adult; D000368:Aged; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy* / Q000209:etiology; D001960:Bromazepam / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged
D014151:Anti-Anxiety Agents; D001960:Bromazepam
Essai clinique du bromazépam. Trente-deux observations.